MX2015006931A - Terapia combinada para tratar cánceres her2-positivos. - Google Patents
Terapia combinada para tratar cánceres her2-positivos.Info
- Publication number
- MX2015006931A MX2015006931A MX2015006931A MX2015006931A MX2015006931A MX 2015006931 A MX2015006931 A MX 2015006931A MX 2015006931 A MX2015006931 A MX 2015006931A MX 2015006931 A MX2015006931 A MX 2015006931A MX 2015006931 A MX2015006931 A MX 2015006931A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- positive cancers
- treating her2
- her2
- her2 antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/16—Holders for containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732736P | 2012-12-03 | 2012-12-03 | |
| US201361810254P | 2013-04-09 | 2013-04-09 | |
| PCT/US2013/072941 WO2014089127A1 (en) | 2012-12-03 | 2013-12-03 | Combination therapy for treating her2-positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015006931A true MX2015006931A (es) | 2016-07-05 |
Family
ID=50883946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006931A MX2015006931A (es) | 2012-12-03 | 2013-12-03 | Terapia combinada para tratar cánceres her2-positivos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9913901B2 (OSRAM) |
| EP (1) | EP2925361A4 (OSRAM) |
| JP (1) | JP2016501234A (OSRAM) |
| KR (1) | KR20150091116A (OSRAM) |
| CN (2) | CN105050619A (OSRAM) |
| AU (1) | AU2013355337B2 (OSRAM) |
| CA (1) | CA2892859A1 (OSRAM) |
| HK (1) | HK1214955A1 (OSRAM) |
| IL (1) | IL239031A0 (OSRAM) |
| MX (1) | MX2015006931A (OSRAM) |
| SG (1) | SG11201504293WA (OSRAM) |
| WO (1) | WO2014089127A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105050619A (zh) | 2012-12-03 | 2015-11-11 | 梅里马克制药公司 | 用于治疗her2-阳性癌症的组合疗法 |
| US9861633B2 (en) * | 2013-07-17 | 2018-01-09 | Foundation Medicine, Inc. | Methods of treating urothelial carcinoma |
| US20160045596A1 (en) * | 2014-08-05 | 2016-02-18 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| WO2017136770A1 (en) * | 2016-02-05 | 2017-08-10 | Merrimack Pharmaceuticals, Inc. | Treatment of her2-intermediate cancer |
| KR102646046B1 (ko) * | 2017-01-06 | 2024-03-08 | 바이오션, 인코포레이티드 | Erbb2 항체 및 이의 용도 |
| CN115957321A (zh) * | 2023-03-03 | 2023-04-14 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US20050084524A1 (en) | 1998-09-30 | 2005-04-21 | Alza Corporation | Method for potentiating activity of a chemotherapeutic drug |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| GB0326486D0 (en) | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| US7674456B2 (en) | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| KR20200058588A (ko) * | 2005-01-21 | 2020-05-27 | 제넨테크, 인크. | Ｈｅｒ 항체의 고정 용량 투여법 |
| JP2008536944A (ja) | 2005-04-22 | 2008-09-11 | アルザ・コーポレーシヨン | Ｈｅｒ２細胞受容体を標的とするためのイムノリポソーム組成物 |
| JP5185813B2 (ja) * | 2005-04-26 | 2013-04-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癌免疫治療のための組成物および方法 |
| BRPI0808055A2 (pt) | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
| CA2700810A1 (en) | 2007-09-28 | 2009-04-02 | Universitatsspital Basel | Immunoliposomes for treatment of cancer |
| EA022201B1 (ru) | 2008-04-11 | 2015-11-30 | Мерримак Фармасьютикалз, Инк. | Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение |
| US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| CN107252417A (zh) * | 2010-12-06 | 2017-10-17 | 梅里麦克制药股份有限公司 | 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药 |
| US20120231066A1 (en) | 2011-01-24 | 2012-09-13 | Henry John Smith | Multi-drug liposomes to treat tumors |
| CN105050619A (zh) | 2012-12-03 | 2015-11-11 | 梅里马克制药公司 | 用于治疗her2-阳性癌症的组合疗法 |
-
2013
- 2013-12-03 CN CN201380070261.4A patent/CN105050619A/zh active Pending
- 2013-12-03 MX MX2015006931A patent/MX2015006931A/es unknown
- 2013-12-03 JP JP2015545523A patent/JP2016501234A/ja active Pending
- 2013-12-03 US US14/650,250 patent/US9913901B2/en not_active Expired - Fee Related
- 2013-12-03 AU AU2013355337A patent/AU2013355337B2/en not_active Expired - Fee Related
- 2013-12-03 EP EP13860427.7A patent/EP2925361A4/en not_active Withdrawn
- 2013-12-03 CN CN201710112540.2A patent/CN107412163A/zh active Pending
- 2013-12-03 WO PCT/US2013/072941 patent/WO2014089127A1/en not_active Ceased
- 2013-12-03 HK HK16102942.7A patent/HK1214955A1/zh unknown
- 2013-12-03 KR KR1020157017006A patent/KR20150091116A/ko not_active Withdrawn
- 2013-12-03 CA CA2892859A patent/CA2892859A1/en not_active Abandoned
- 2013-12-03 SG SG11201504293WA patent/SG11201504293WA/en unknown
-
2015
- 2015-05-27 IL IL239031A patent/IL239031A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105050619A (zh) | 2015-11-11 |
| CN107412163A (zh) | 2017-12-01 |
| US20160250328A1 (en) | 2016-09-01 |
| EP2925361A1 (en) | 2015-10-07 |
| KR20150091116A (ko) | 2015-08-07 |
| US9913901B2 (en) | 2018-03-13 |
| WO2014089127A1 (en) | 2014-06-12 |
| AU2013355337B2 (en) | 2018-07-12 |
| JP2016501234A (ja) | 2016-01-18 |
| EP2925361A4 (en) | 2016-06-29 |
| HK1214955A1 (zh) | 2016-08-12 |
| SG11201504293WA (en) | 2015-06-29 |
| CA2892859A1 (en) | 2014-06-12 |
| AU2013355337A1 (en) | 2015-07-09 |
| IL239031A0 (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015006931A (es) | Terapia combinada para tratar cánceres her2-positivos. | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| NZ719368A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
| MX349198B (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| EP3606964A4 (en) | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY | |
| BR112015023910A2 (pt) | terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer | |
| IN2015KN00350A (OSRAM) | ||
| CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
| PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| HK1258921A1 (zh) | Flt3 定向 car 细胞免疫疗法 | |
| NZ716473A (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
| WO2016051398A8 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| PH12020551715A1 (en) | Methods of treating cancer | |
| MX2020001727A (es) | Terapia de combinacion. | |
| PH12014501543A1 (en) | Combination therapy for the treatment of ovarian cancer | |
| MX2016001541A (es) | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. | |
| MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
| MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
| MX2022006155A (es) | Terapias anticancerosas con anamicina liposomica orientadas al pulmon. | |
| NZ701974A (en) | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation | |
| MX2015004703A (es) | Composiciones cancerigenas inyectables. | |
| WO2018231799A8 (en) | Methods of treating brain tumors using combination therapy | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. |